Genmab — April 2026

[Raun]

Information om RAINFOL-06 og -07 studiernes fokus på yderligere kombinationsbehandlinger og nye indikationer for Folat Receptor alfa (FRα) findes i Genmabs investorpræsentationer og opdaterede pipelinedokumenter. Disse strategiske udvidelser og den generelle Rina-S programacceleration beskrives i selskabets finansielle rapporter, herunder materialer relateret til deres Q3 2025 Interim Report og 2025 Annual Report

[ProinvestorNEWS]

Genmab i kridthuset hos Goldman: Ser potentiale på 27 pct. https://proinvestor.com/investornyt/1434655/genmab-i-kridthuset-hos-goldman-ser-potentiale-pa-27-pct

[E_L]

ok, so AI does not know more than we do. RAINFOL-06 to 08 was not mentioned anywhere before. It is logical to assume these names are in use for other indications so we'll have to wait to see which indications they are and if initial data is sufficiently strong to bring them into trial. Breast cancer maybe?

[E_L]

Or maybe cervical cancer which could explain the silence on further development of Tivdak, I would not be surprised to see efficacy with Rina-S at a much better tox profile than Tivdak

[E_L]

https://x.com/StockwatchDK/status/2046891046001381686 on Goldman

[E_L]

BNP Paribas Upgrades Genmab to Outperform from Neutral, Boosts PT to dkk2.400 (from 1.300)

MT Newswires
·
Apr 22 2026

[JKY_VH]

Sikke et pludseligt klarsyn og god formiddag:-)

[Bella1]

Louis Nielsen har nok åbnet butik i Frankrig

[JKY_VH]

[JKY_VH]

[ProinvestorNEWS]

"The winner takes it all" . Det globale aktiemarked er presset for tiden - men for NASDAQ-indekset i USA kører det forrygende. Der sættes hele tiden nye kursrekorder trods krig, stigende oliepriser osv. Helge Larsen ser på årsagerne og kommer sidst i ugekommentaren også ind på, hvorfor pharma ikke er en sikker havn i disse urolige tider. Kort video: https://proinvestor.com/boards/132062

[E_L]

Petosemtamab Ph3 goes from 500 to 700 patients , same completion dates
https://clinicaltrials.gov/study/NCT06525220

[Sukkeralf]

Just a moment...

(www.fiercebiotech.com)

[Sukkeralf]

Nogen der kender til succesrige selskaber indenfor dette felt

[Sukkeralf]

ISACs

[JKY_VH]

Mim8 fra Børsen "Rival skoser udfordrer fra Novo Nordisk". “Vi ser faktisk ikke rigtig nogen klinisk forskel i forhold til Mim8 for at være ærlig,” siger Teresa Graham, adm. direktør for Roche Pharmaceuticals, om de to produkter.", men det skal han jo sige.

[JKY_VH]

"Analytikerne estimerer, at Novo Nordisks produkt når et topsalg på 12 mia. kr. i midten af næste årti – en del under salget af Hemlibra, der nåede tæt på 38 mia. kr. i 2025", skriver Børsen https://borsen.dk/nyheder/virksomheder/rival-skoser-udfordrer-fra-novo-nordisk?b_source=borsen&b_medium=row_0&b_campaign=news_3

[E_L]

@SugarAlf Bolt has the Boltbody ISAC platform which Genmab collaborates on. no signs of success yet i think

[Sukkeralf]

No so far the no promissing results from Bolt and I would think an IND in the Genmab collaboration is a bit overdue or maybe even dropped. But Bolt is cheap so any success could catapult the stock up high

[E_L]

if there is ANY chance of success on one of the Genmab ISAC's they should just buy Bolt at this price...